Stereotactic Ablative Radiotherapy Uncertainties

Delineation, Setup and Motion

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy, is biologically distinct from conventionally fractionated radiotherapy in that it is ablative, causing functional incapacitation of targeted tissue including margins added to avoid errors. In striking contrast, small 1.8-2 Gy daily doses associated with historical fractionated radiotherapy cause more modest injury more likely to be repaired by normal tissue than tumor. Strategic plans to deal with uncertainties in tumor location, motion during treatment, dose deposition and heterogeneity effects, and tolerance require a novel approach for SAbR very different from what has been dogma for conventionally fractionated treatments. In essence, the targets must be kept absolutely as small as prudently possible without missing tumor deposits. Given the potency and clinical potential of SAbR, a more sophisticated and rigorous approach to uncertainties and margins is warranted.

Original languageEnglish (US)
JournalSeminars in Radiation Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Uncertainty
Radiotherapy
Neoplasms
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{b72e29c7f3d64d1bacac2d105849137b,
title = "Stereotactic Ablative Radiotherapy Uncertainties: Delineation, Setup and Motion",
abstract = "Stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy, is biologically distinct from conventionally fractionated radiotherapy in that it is ablative, causing functional incapacitation of targeted tissue including margins added to avoid errors. In striking contrast, small 1.8-2 Gy daily doses associated with historical fractionated radiotherapy cause more modest injury more likely to be repaired by normal tissue than tumor. Strategic plans to deal with uncertainties in tumor location, motion during treatment, dose deposition and heterogeneity effects, and tolerance require a novel approach for SAbR very different from what has been dogma for conventionally fractionated treatments. In essence, the targets must be kept absolutely as small as prudently possible without missing tumor deposits. Given the potency and clinical potential of SAbR, a more sophisticated and rigorous approach to uncertainties and margins is warranted.",
author = "Ming Yang and Robert Timmerman",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.semradonc.2018.02.006",
language = "English (US)",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Stereotactic Ablative Radiotherapy Uncertainties

T2 - Delineation, Setup and Motion

AU - Yang, Ming

AU - Timmerman, Robert

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy, is biologically distinct from conventionally fractionated radiotherapy in that it is ablative, causing functional incapacitation of targeted tissue including margins added to avoid errors. In striking contrast, small 1.8-2 Gy daily doses associated with historical fractionated radiotherapy cause more modest injury more likely to be repaired by normal tissue than tumor. Strategic plans to deal with uncertainties in tumor location, motion during treatment, dose deposition and heterogeneity effects, and tolerance require a novel approach for SAbR very different from what has been dogma for conventionally fractionated treatments. In essence, the targets must be kept absolutely as small as prudently possible without missing tumor deposits. Given the potency and clinical potential of SAbR, a more sophisticated and rigorous approach to uncertainties and margins is warranted.

AB - Stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy, is biologically distinct from conventionally fractionated radiotherapy in that it is ablative, causing functional incapacitation of targeted tissue including margins added to avoid errors. In striking contrast, small 1.8-2 Gy daily doses associated with historical fractionated radiotherapy cause more modest injury more likely to be repaired by normal tissue than tumor. Strategic plans to deal with uncertainties in tumor location, motion during treatment, dose deposition and heterogeneity effects, and tolerance require a novel approach for SAbR very different from what has been dogma for conventionally fractionated treatments. In essence, the targets must be kept absolutely as small as prudently possible without missing tumor deposits. Given the potency and clinical potential of SAbR, a more sophisticated and rigorous approach to uncertainties and margins is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85048157813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048157813&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2018.02.006

DO - 10.1016/j.semradonc.2018.02.006

M3 - Article

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

ER -